SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. 2000. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60: 57615766.
  • Basu A, Krishnamurthy S. 2010. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids pii: 201367.
  • Borst P, Schinkel AH. 1997. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 13: 217222.
  • Brozovic A, Ambriović-Ristov A, Osmak M. 2010. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 40: 347359.
  • Chaney SG, Campbell SL, Bassett E, Wu Y. 2005. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53: 311.
  • Chang XB. 2010. Molecular mechanism of ATP-dependent solute transport by multidrug resistance-associated protein 1. Methods Mol Biol 596: 223249.
  • Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM, Song EY, Lim JS, Yoon DY, Lee HG, Choe YK. 2006. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237: 5666.
  • De Milito A, Fais S. 2005. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 1: 779786.
  • Heimlich G, Cidlowski JA. 2006. Selective role of intracellular chloride in the regulation of the intrinsic but not extrinsic pathway of apoptosis in Jurkat T–cells. J Biol Chem 281: 4222242231.
  • Huang CR, Jin ZX, Dong L, Tong XP, Yue S, Kawanami T, Sawaki T, Sakai T, Miki M, Iwao H, Nakajima A, Masaki Y, Fukushima Y, Tanaka M, Fujita Y, Nakajima H, Okazaki T, Umehara H. 2010. Cisplatin augments FAS-mediated apoptosis through lipid rafts. Anticancer Res 30: 20652071.
  • Ise T, Shimizu T, Lee EL, Inoue H, Kohno K, Okada Y. 2005. Roles of volume-sensitive Cl channel in cisplatin-induced apoptosis in human epidermoid cancer cells. Membrane Biol 205: 139145.
  • Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ. 2009. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53- dependent and p53-independent responses. Int J Oncol 401416.
  • Kunzelmann K. 2005. Ion channels and cancer. J Membr Biol 205: 159173.
  • Lang F, Föller M, Lang KS, Lang PA, Ritter M, Gulbins E, Vereninov A, Huber SM. 2005. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol 205: 147157.
  • Lang F, Shumilina E, Ritter M, Gulbins E, Vereninov A, Huber SM. 2006. Ion channels and cell volume in regulation of cell proliferation and apoptotic cell death. Contrib Nephrol 152: 142160.
  • Loehrer PJ, Einhorn LH. 1984. Drugs five years later: Cisplatin. Ann Int Med 100: 704713.
  • Millot C, Millot JM, Morjani H, Desplaces A, Manfait M. 1997. Characterization of acidic vesiclues in multidrug-resistant and sensitive cancer cells by Acridine Orange staining and confocal microspectrofluorometry. J Histochem Cytochem 45: 12551264.
  • Muggia F. 2009. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112: 275281.
  • Okada Y, Maeno E, Shimizu T, Dezaki K, Wang J, Morishima S. 2001. Receptor- mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD). J Physiol 532: 316.
  • Okada Y, Maeno E, Shimizu T, Manabe K, Mori S, Nabekura T. 2004. Dual roles of plasmalemmal chloride channels in induction of cell death. Eur J Physiol 448: 287295.
  • Olszewski U, Hamilton G. 2010. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem 10: 293301.
  • Panczyk M, Sałagacka A, Mirowski M. 2007. MDR1 (ABCB1) gene encoding glycoprotein P (P-gp), a member of ABC transporter superfamily: consequences for therapy and progression of neoplastic diseases. Postepy Biochem 53: 361373.
  • Piulats JM, Jiménez L, García del Muro X, Villanueva A, Viñals F, Germà-Lluch JR. 2009. Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clin Transl Oncol 11: 780786.
  • Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. 2008. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 15: 26562663.
  • Reedijk J. 2003. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Special Feature Perspective 100: 36113616.
  • Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB. 2005. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 11: 756767.
  • Shimizu S, Konishi A, Kodama T, Tsujimoto Y. 2000. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci USA 97: 31003105.
  • Shimizu S, Narita M, Tsujimoto Y. 1999. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483487.
  • Shimizu T, Numata T, Okada Y. 2004. A role of reactive oxygen species in apoptotic activation of volume-sensitive Cl- channel. Proc Natl Acad Sci USA 101: 67706773.
  • Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. 2009. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64: 11151122.
  • Tafani M, Cohn JA, Karpinich NO, Rothman RJ, Russo MA, Farber JL. 2002. Regulation of intracellular pH mediates Bax activation in HeLa cells treated with staurosporine or tumor necrosis factor-alpha[J]. J Biol Chem 277: 4956949576.
  • Wang D, Lippard SJ. 2005. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307320.
  • Wernyj RP, Morin PJ. 2004. Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel. Drug Resist Update 7: 227232.
  • Weylandt KH, Nebrig M, Jansen-Rosseck N, Amey JS, Carmena D, Wiedenmann B, Higgins CF, Sardini A. 2007. ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment. Mol Cancer Ther 6: 979986.
  • Wondergem R, Gong W, Monen SH, Dooley SN, Gonce JL, Conner TD, Houser M, Ecay TW, Ferslew KE. 2001. Blocking swelling-activated chloride current inhibits mouse liver cell proliferation. J Physiol 532: 661672.
  • Wozniak K, Blasiak J. 2002. Recognition and repair of DNA-cisplatin adducts. Quarterly 49: 583596.